Semaglutide Linked to Lower Bone Fracture Risk in Type 2 Diabetes Patients

Semaglutide use is linked to a 15% lower risk of bone fractures compared to other weight-loss medications in adults with type 2 diabetes, according to a study presented Sunday at ENDO 2026. The research, led by Jairo Noreña, M.D., found that patients using the drug experienced greater weight loss and fewer fractures than those using alternative anti-obesity treatments.

How does semaglutide affect bone health and weight?

Patients treated with semaglutide saw a larger reduction in body mass index (BMI) than those in the comparison group, according to the study presented at the Endocrine Society’s annual meeting in Chicago, Illinois. The data showed a clear difference in fracture rates between the groups.

Researchers recorded 794 fractures among semaglutide users. In contrast, the control group experienced 1,045 fractures.

Did You Know? The researchers utilized the Atropos Health Eos electronic health record database, which contains data from 161 million patients treated at academic medical centers and community hospitals in the U.S.

Why is this finding significant for diabetes patients?

This result contrasts with previous research suggesting that the rapid weight loss associated with GLP-1 medications could cause bone thinning and increase fracture risk. While gradual weight loss is generally thought to preserve bone density, semaglutide’s impact compared to other weight-loss drugs had not been well studied.

“Bone fractures are painful, expensive and can seriously affect quality of life — especially as people get older,” Noreña said. He noted that the study’s goal is to encourage the monitoring of bone health within weight-loss programs.

Expert Insight: Samantha Carter notes that these findings challenge the assumption that rapid weight loss necessarily compromises skeletal integrity. The data suggests a possible protective effect that could shift how clinicians balance aggressive weight reduction with long-term bone preservation in high-risk diabetic populations.

How was the semaglutide study conducted?

Researchers performed a retrospective cohort study analyzing data from January 2016 to December 2023. The study focused on adults age 18 and older with type 2 diabetes who had no history of osteoporosis medication use or previous fractures.

Endocrinology Update – 24 Mar 2026: Retatrutide Phase 3, Generic Semaglutide and More

The semaglutide group consisted of 26,324 patients. The comparison group included 33,555 patients who received dulaglutide, bupropion/naltrexone, or phentermine/topiramate and had no prior history of semaglutide use.

What happens next for these findings?

The current results point toward a possible protective effect on bone health, but they are not yet definitive. Researchers stated that additional prospective studies may be needed to confirm the association between semaglutide and reduced fracture risk.

This work is considered an early step in understanding how semaglutide-induced weight loss specifically impacts the bones of patients with type 2 diabetes, according to Noreña.

Frequently Asked Questions

Which medications were compared against semaglutide?
The comparison group included patients taking dulaglutide, as well as the oral weight-loss therapies bupropion/naltrexone and phentermine/topiramate.

What was the specific reduction in fracture risk?
According to the study, semaglutide use was linked to a 15% lower risk of bone fractures compared with the alternative weight-loss medications.

Who participated in the study?
The analysis included adults 18 and older with type 2 diabetes who had not taken osteoporosis medications and had no previous fractures.

Do you believe bone health should be a standard part of weight-loss medication monitoring?